Patrick McEnany, CEO of Catalyst Pharmaceuticals, bought 25,000 shares of Catalyst Pharmaceuticals (Stock Symbol: CPRX) at $1.82 per share for a total amount of $45.5 thousand on February 7, 2014.
Catalyst Pharmaceuticals is located in Coral Gables, Florida.
On Feb. 6th, 2014, Catalyst Pharmaceutical announced that the Company will be presenting at the 16th Annual BIO CEO & Investor Conference, in New York. Patrick J. McEnany, Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/Chief Operating Officer at Catalyst, will provide an overview of the Company and its key programs on Tuesday, February 11, at 1:00 p.m. ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation..
On November 14, 2013, Catalyst Pharmaceutical Partners, Inc. (CPRX) a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced financial results for the third quarter and nine months period ended September 30, 2013. “Significant progress has been made towards initiating new clinical trial sites and enrolling patients in our Phase 3 clinical trial for Firdapse™ to treat patients with Lambert-Eaton Myasthenic Syndrome (LEMS). We continue to believe that we will complete enrollment around the end of the year and be in a position to announce top-line data from the double-blind portion of our trial during the second quarter of 2014,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer. “The Catalyst team is focused on all critical activities to successfully complete our Phase 3 registration trial and has begun its pre-commercialization efforts for Firdapse™.”
According to Capital IQ, Catalyst Pharmaceutical Partners, Inc. has a market cap of $105.02 million and an enterprise value of $75.74 million.
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The companys principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Patrick McEnany’s most recent annual compensation from Catalyst Pharmaceutical is a salary of $394,596, $66,409 in other compensation, and a total compensation of $461,005. Mr. McEnany is 65 years old.
According to his biography, Mr. Patrick J. McEnany is the Chairman of the Board, President, Chief Executive Officer of Catalyst Pharmaceutical Partners, Inc. Mr. McEnany has been CEO and a director since formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on the board of directors for ThermoGenesis Corp. and the Jackson Memorial Hospital Foundation, and over the last 30 years has served as a director for numerous other public companies.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.
Recent Comments